Company Overview and News

10
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-07-20 zacks
Making its debut on 02/23/2012, smart beta exchange traded fund iShares Emerging Markets Dividend ETF (DVYE - Free Report) provides investors broad exposure to the Broad Emerging Market ETFs category of the market.
SSW KDP IEMG SSWN DVYE SSW.PRC SSW.PRH SSW.PRG SSW.PRE SSW.PRD VWO SSWA

44
7 Best Vanguard Funds for the Second Half of 2018 | InvestorPlace

2018-07-11 investorplace
The S&P 500 gained 2.5% in the first half of the year, delivering a decent though not jaw-dropping performance. With the second half of the year, now could be an ideal time for some investors to consider reconfiguring their portfolios or buy some of the first half’s outperforming (or laggard) funds.
FB AMZN T GOOGL VIGI AAPL VZ NFLX NYTAB GOOG VBK VWO

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-07-02 zacks
The First Trust BICK Index Fund (BICK - Free Report) made its debut on 04/12/2010, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

5
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-06-27 zacks
The SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) made its debut on 02/23/2011, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
5347 EDIV TNABY IEMG UMC PETFF TNABF ICHR VWO

0
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-06-25 zacks
Making its debut on 02/23/2012, smart beta exchange traded fund iShares Emerging Markets Dividend ETF (DVYE - Free Report) provides investors broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
DVYE SSW IEMG SSW.PRC SSW.PRH SSW.PRG SSW.PRE SSWN SSW.PRD VWO SSWA

0
4 EM ETFs Almost Unscathed by Steep EM Selloffs

2018-06-20 zacks
Emerging markets (EM) investing no longer seems a winning proposition now. The space had a stellar run in 2017, when the broader emerging market fund iShares MSCI Emerging Markets ETF (EEM - Free Report) returned about 35.6%, marking its best year since 2009, thanks to a subdued greenback and synchronized global growth.
VWO EEM

0
Most Asset Classes Fell Last Week

2018-06-18 seekingalpha
Selling dominated global markets in last week's trading. US stocks and bonds posted gains, but the rest of the major asset classes retreated over the five trading days through June 15, based on a set of exchange-traded products.
VWO

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-06-08 zacks
A smart beta exchange traded fund, the First Trust BICK Index Fund (BICK - Free Report) debuted on 04/12/2010, and offers broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-06-07 zacks
The First Trust BICK Index Fund (BICK - Free Report) made its debut on 04/12/2010, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

2
Emerging Markets - What Now?

2018-06-02 seekingalpha
The Emerging Markets ended a 10-year bear market in Q1 '16, as the EEM (iShares MSCI Emerging Markets ETF) peaked in the $55 area in October 2007, the VWO (Vanguard FTSE Emerging Markets ETF) peaked near $58 in November 2007, where both bottomed in Q1 '16 near $30 per share.
PBR VWO EEM

343
7 Stocks the Great Investors Have Bet Big On

2018-05-31 investorplace
When regular investors think about which stocks to buy, we often fail to consider the institutions or billionaire investors backing these companies. The great investors often will bet big on a company’s long term prospects.
LOW NWL HD BRK.A JCP MU AAPL WDC UAL VWO

14
Cheap Country Corner: A True Turkey?

2018-05-18 seekingalpha
At Cheap Country Corner we focus on the stock market of a country that has recently experienced significant downside (in USD terms) and ask: How cheap is it?
0941 TUR VT CHLKF CHL TKF VWO

32
How To Choose The Best China ETF Allocation, After Vanguard's First All-China ETF

2018-05-18 seekingalpha
This month, Vanguard launched its first "total China"-focused ETF in Hong Kong, covering A-shares, H-shares, P, N, B, S and Red Chips for 40bps.
HKXCY MCHI DSUM EWH IEMG 2846 EWT BLK 2800 HAHA VWO EEM

0
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-05-10 zacks
The iShares Emerging Markets Dividend ETF (DVYE - Free Report) made its debut on 02/23/2012, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
DVYE SSW IEMG SSW.PRC SSW.PRH SSW.PRG SSW.PRE SSWN SSW.PRD VWO SSWA

0
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?

2018-05-03 zacks
Launched on 04/12/2010, the First Trust BICK Index Fund (BICK - Free Report) is a smart beta exchange traded fund offering broad exposure to the Broad Emerging Market ETFs category of the U.S. equity market.
MMYT BICK IEMG YTRA VWO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 922042858